Repros Seeks To Develop Low-Dose Proellex To Avoid Liver Toxicity

In a precarious financial situation, the company requests that FDA lift a clinical hold on the drug it is developing for uterine fibroids and endometriosis.

More from Archive

More from Pink Sheet